The Medicines and Healthcare products Regulatory Agency (MHRA) have issued a Valproate National Patient Safety Alert in advance of new regulatory measure being introduced from January 2024.
The alert calls on Integrated Care Boards (in England) and Health Boards (in Scotland and Wales) to designate a new or existing group to prepare for and co-ordinate the implementation of the new regulatory measures for oversight of prescribing valproate to new patients and existing female patients.
Pharmacy teams should continue to dispense valproate. They should be prepared to discuss the current warnings and upcoming measures with their patients.
We have sent an email update to all pharmacy professionals to highlight this National Patient Safety Alert.